Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Merck Releases Q4 Earnings Stays Bullish On COVID-19 Pill Sales – $MRK $DIA

By John F. Heerdink, Jr.

Reportedly, Merck & Co., Inc. (MRK) released fourth-quarter earnings recently. They confirmed that they expecting its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir. The drugmaker also informed that the sales of the COVID-19 drug were $952 million in the fourth quarter, and it expects another $5 to $6 billion of sales for the drug in 2022.

Merck posted fourth-quarter earnings of $4.58 billion, or $1.80 a share, up from last year of $2.49 billion, or 98 cents a share. Analysts were expecting earnings of $1.53 a share. Sales were $13.52 billion in the quarter beating estimates at $13.2 billion and up from $10.95 billion last year, boosted by the molnupiravir sales and growth from cancer drug Keytruda and human papillomavirus (HPV) vaccine Gardasil.

Merck expects 2022 earnings to be between $7.12 and $7.27 a share, below analyst forecasts of $7.29 a share. It is forecasting 2022 revenue to be between $56.1 billion and $57.6 billion, an increase from $48.7 billion last year. CFO Litchfield informed that the company plans to reinvest much of the cash from what could be a one-year windfall from molnupiravir back in its business, and also to support business development.

“Our goal is to do meaningful business development. Should that not materialize, we would increase the level of share buybacks that we would do,” stated CFO Caroline Litchfield.

Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Stay Informed! Stay Competitive! Please join us at Vista Partners to receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.


(Read Original Story: Merck sees 2022 sales up nearly 20%, mostly on molnupiravir in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us